Cargando…

Advancing Optical Imaging for Breast Margin Assessment: An Analysis of Excisional Time, Cautery, and Patent Blue Dye on Underlying Sources of Contrast

Breast conserving surgery (BCS) is a recommended treatment for breast cancer patients where the goal is to remove the tumor and a surrounding rim of normal tissue. Unfortunately, a high percentage of patients return for additional surgeries to remove all of the cancer. Post-operative pathology is th...

Descripción completa

Detalles Bibliográficos
Autores principales: Bydlon, Torre M., Barry, William T., Kennedy, Stephanie A., Brown, J. Quincy, Gallagher, Jennifer E., Wilke, Lee G., Geradts, Joseph, Ramanujam, Nimmi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3519619/
https://www.ncbi.nlm.nih.gov/pubmed/23251526
http://dx.doi.org/10.1371/journal.pone.0051418
_version_ 1782252700961865728
author Bydlon, Torre M.
Barry, William T.
Kennedy, Stephanie A.
Brown, J. Quincy
Gallagher, Jennifer E.
Wilke, Lee G.
Geradts, Joseph
Ramanujam, Nimmi
author_facet Bydlon, Torre M.
Barry, William T.
Kennedy, Stephanie A.
Brown, J. Quincy
Gallagher, Jennifer E.
Wilke, Lee G.
Geradts, Joseph
Ramanujam, Nimmi
author_sort Bydlon, Torre M.
collection PubMed
description Breast conserving surgery (BCS) is a recommended treatment for breast cancer patients where the goal is to remove the tumor and a surrounding rim of normal tissue. Unfortunately, a high percentage of patients return for additional surgeries to remove all of the cancer. Post-operative pathology is the gold standard for evaluating BCS margins but is limited due to the amount of tissue that can be sampled. Frozen section analysis and touch-preparation cytology have been proposed to address the surgical needs but also have sampling limitations. These issues represent an unmet clinical need for guidance in resecting malignant tissue intra-operatively and for pathological sampling. We have developed a quantitative spectral imaging device to examine margins intra-operatively. The context in which this technology is applied (intra-operative or post-operative setting) is influenced by time after excision and surgical factors including cautery and the presence of patent blue dye (specifically Lymphazurin™, used for sentinel lymph node mapping). Optical endpoints of hemoglobin ([THb]), fat ([β-carotene]), and fibroglandular content via light scattering (<µ(s)’>) measurements were quantified from diffuse reflectance spectra of lumpectomy and mastectomy specimens using a Monte Carlo model. A linear longitudinal mixed-effects model was used to fit the optical endpoints for the cautery and kinetics studies. Monte Carlo simulations and tissue mimicking phantoms were used for the patent blue dye experiments. [THb], [β-carotene], and <µ(s)’> were affected by <3.3% error with <80 µM of patent blue dye. The percent change in [β-carotene], <µ(s)’>, and [β-carotene]/<µ(s)’> was <14% in 30 minutes, while percent change in [THb] was >40%. [β-carotene] and [β-carotene]/<µ(s)’> were the only parameters not affected by cautery. This work demonstrates the importance of understanding the post-excision kinetics of ex-vivo tissue and the presence of cautery and patent blue dye for breast tumor margin assessment, to accurately interpret data and exploit underling sources of contrast.
format Online
Article
Text
id pubmed-3519619
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-35196192012-12-18 Advancing Optical Imaging for Breast Margin Assessment: An Analysis of Excisional Time, Cautery, and Patent Blue Dye on Underlying Sources of Contrast Bydlon, Torre M. Barry, William T. Kennedy, Stephanie A. Brown, J. Quincy Gallagher, Jennifer E. Wilke, Lee G. Geradts, Joseph Ramanujam, Nimmi PLoS One Research Article Breast conserving surgery (BCS) is a recommended treatment for breast cancer patients where the goal is to remove the tumor and a surrounding rim of normal tissue. Unfortunately, a high percentage of patients return for additional surgeries to remove all of the cancer. Post-operative pathology is the gold standard for evaluating BCS margins but is limited due to the amount of tissue that can be sampled. Frozen section analysis and touch-preparation cytology have been proposed to address the surgical needs but also have sampling limitations. These issues represent an unmet clinical need for guidance in resecting malignant tissue intra-operatively and for pathological sampling. We have developed a quantitative spectral imaging device to examine margins intra-operatively. The context in which this technology is applied (intra-operative or post-operative setting) is influenced by time after excision and surgical factors including cautery and the presence of patent blue dye (specifically Lymphazurin™, used for sentinel lymph node mapping). Optical endpoints of hemoglobin ([THb]), fat ([β-carotene]), and fibroglandular content via light scattering (<µ(s)’>) measurements were quantified from diffuse reflectance spectra of lumpectomy and mastectomy specimens using a Monte Carlo model. A linear longitudinal mixed-effects model was used to fit the optical endpoints for the cautery and kinetics studies. Monte Carlo simulations and tissue mimicking phantoms were used for the patent blue dye experiments. [THb], [β-carotene], and <µ(s)’> were affected by <3.3% error with <80 µM of patent blue dye. The percent change in [β-carotene], <µ(s)’>, and [β-carotene]/<µ(s)’> was <14% in 30 minutes, while percent change in [THb] was >40%. [β-carotene] and [β-carotene]/<µ(s)’> were the only parameters not affected by cautery. This work demonstrates the importance of understanding the post-excision kinetics of ex-vivo tissue and the presence of cautery and patent blue dye for breast tumor margin assessment, to accurately interpret data and exploit underling sources of contrast. Public Library of Science 2012-12-10 /pmc/articles/PMC3519619/ /pubmed/23251526 http://dx.doi.org/10.1371/journal.pone.0051418 Text en © 2012 Bydlon et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Bydlon, Torre M.
Barry, William T.
Kennedy, Stephanie A.
Brown, J. Quincy
Gallagher, Jennifer E.
Wilke, Lee G.
Geradts, Joseph
Ramanujam, Nimmi
Advancing Optical Imaging for Breast Margin Assessment: An Analysis of Excisional Time, Cautery, and Patent Blue Dye on Underlying Sources of Contrast
title Advancing Optical Imaging for Breast Margin Assessment: An Analysis of Excisional Time, Cautery, and Patent Blue Dye on Underlying Sources of Contrast
title_full Advancing Optical Imaging for Breast Margin Assessment: An Analysis of Excisional Time, Cautery, and Patent Blue Dye on Underlying Sources of Contrast
title_fullStr Advancing Optical Imaging for Breast Margin Assessment: An Analysis of Excisional Time, Cautery, and Patent Blue Dye on Underlying Sources of Contrast
title_full_unstemmed Advancing Optical Imaging for Breast Margin Assessment: An Analysis of Excisional Time, Cautery, and Patent Blue Dye on Underlying Sources of Contrast
title_short Advancing Optical Imaging for Breast Margin Assessment: An Analysis of Excisional Time, Cautery, and Patent Blue Dye on Underlying Sources of Contrast
title_sort advancing optical imaging for breast margin assessment: an analysis of excisional time, cautery, and patent blue dye on underlying sources of contrast
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3519619/
https://www.ncbi.nlm.nih.gov/pubmed/23251526
http://dx.doi.org/10.1371/journal.pone.0051418
work_keys_str_mv AT bydlontorrem advancingopticalimagingforbreastmarginassessmentananalysisofexcisionaltimecauteryandpatentbluedyeonunderlyingsourcesofcontrast
AT barrywilliamt advancingopticalimagingforbreastmarginassessmentananalysisofexcisionaltimecauteryandpatentbluedyeonunderlyingsourcesofcontrast
AT kennedystephaniea advancingopticalimagingforbreastmarginassessmentananalysisofexcisionaltimecauteryandpatentbluedyeonunderlyingsourcesofcontrast
AT brownjquincy advancingopticalimagingforbreastmarginassessmentananalysisofexcisionaltimecauteryandpatentbluedyeonunderlyingsourcesofcontrast
AT gallagherjennifere advancingopticalimagingforbreastmarginassessmentananalysisofexcisionaltimecauteryandpatentbluedyeonunderlyingsourcesofcontrast
AT wilkeleeg advancingopticalimagingforbreastmarginassessmentananalysisofexcisionaltimecauteryandpatentbluedyeonunderlyingsourcesofcontrast
AT geradtsjoseph advancingopticalimagingforbreastmarginassessmentananalysisofexcisionaltimecauteryandpatentbluedyeonunderlyingsourcesofcontrast
AT ramanujamnimmi advancingopticalimagingforbreastmarginassessmentananalysisofexcisionaltimecauteryandpatentbluedyeonunderlyingsourcesofcontrast